UBE2V2 Positively Correlates With PD-L1 Expression and Confers Poor Patient Survival in Lung Adenocarcinoma

Abstract

This research aims to explore the diagnostic and prognostic value of ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2) in lung adenocarcinoma (LUAD). The expression of UBE2V2 in clinical specimens was evaluated by bioinformatics analyses and immunohistochemistry. Bioinformatics analyses relying on the The Cancer Genome Atlas (TCGA) database suggested the elevated UBE2V2 mRNA levels in LUAD in comparison to adjacent normal tissues. Gene set enrichment analyses and gene ontology term enrichment analyses further showed the involvement of UBE2V2 in the modulation of cell cycle and immune associated signaling. The correlation analyses in TCGA LUAD data set revealed the positive correlation between UBE2V2 and CCNE1, CCNE2, CCNA2, CCNB1, CCNB2, cyclin-dependent kinase (CDK)2, CDK4, and CDK1 at the mRNA level. Moreover, UBE2V2 mRNA levels were positively correlated with PD-L1 mRNA levels, the T classification, and poor survival of LUAD patients, and were negatively correlated with type II interferon response. Consistent with the results obtained from TCGA data mining, immunohistochemistry demonstrated that UBE2V2 protein levels were upregulated in LUAD in comparison to normal tissues and were positively associated with T classification. Intriguingly, a positive correlation between UBE2V2 protein levels and PD-L1 expression was also elucidated in clinical samples. Besides, UBE2V2 expression indicated a poor prognosis in LUAD patients. Our study found that UBE2V2 was identified as an independent prognostic indicator for LUAD and might serve as an alternative target for LUAD treatment.

miR-499a inhibits the proliferation and apoptosis of prostate cancer via targeting UBE2V2

“…Previous studies have shown that UBE2V2 is related to the occurrence and development of various tumors. The study by Hua zhi-dan et al has shown that the expression of UBE2V2 in lung adenocarcinoma is positively correlated with PD-L 1 [21]. And the expression of UBE2V2 is negatively correlated with the severity of lung adenocarcinoma.…”

“…They have sequence similarity to other ubiquitinconjugating enzymes but lack the conserved cysteine residues that are essential for the catalytic activity of E2 [19,20]. Current research shows that the protein may be closely related to the differentiation of a variety of cells [21]. In the previous screening of miRNA libraries targeting prostate cancer cells to regulate miRNAs, we found that miR-499a is significantly under-expressed in several prostate cancer cell populations, and we have also detected abnormally low expression of miR-499a in prostate cancer tissue samples.…”

A Ubiquitin-Proteasome Gene Signature for Predicting Prognosis in Patients With Lung Adenocarcinoma

“…UBE2V2 (ubiquitin-conjugating enzyme E2 variant 2) has sequence similarity to other ubiquitin-conjugating enzymes but lacks the conserved cysteine residues that are essential for the catalytic activity of E2 ( Dikshit et al, 2018 ; Zhao et al, 2018 ). Hua et al reported that UBE2V2 was identified as an independent prognostic indicator for LUAD and might function as a therapeutic target Hua et al (2021) .…”

Analysis of potential genetic biomarkers and molecular mechanism of smoking-related postmenopausal osteoporosis using weighted gene co-expression network analysis and machine learning

“…UBE2V2 contributes to the development and progression of many cancers, including prostate, oropharyngeal, and breast cancers, via promoting cell proliferation, suppressing cell apoptosis, and regulating immune signaling [ 71 – 73 ]. Moreover, UBE2V2 is an independent prognostic indicator for lung adenocarcinoma, which is closely related to the mutational processes of cigarette smoking [ 74 , 75 ]. RPS16 contributes to facilitate tumor progression of glioma via the PI3K/AKT signaling [ 76 ].…”